University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Public Health Resources

Public Health Resources

4-19-2012

Molecular distinctions between pediatric and adult mature B-cell
non-Hodgkin lymphomas identified through genomic profiling
Karen Deffenbacher
University of Nebraska Medical Center, Omaha

Javeed Iqbal
University of Nebraska Medical Center, Omaha

Warren Sanger
University of Nebraska Medical Center, Omaha

Yulei Shen
University of Nebraska Medical Center, Omaha

Cynthia Lachel
University of Nebraska Medical Center, Omaha
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources
Part of the Public Health Commons

Deffenbacher, Karen; Iqbal, Javeed; Sanger, Warren; Shen, Yulei; Lachel, Cynthia; Liu, Zhongfeng; Liu,
Yanyan; Lim, Megan; Perkins, Sherrie; Fu, Kai; Smith, Lynette; Lynch, James; Staudt, Louis; Rimsza, Lisa M.;
Jaffe, Elaine; Rosenwald, Andreas; Ott, German; Delabie, Jan; Campo, Elias; Gascoyne, Randy; Cairo,
Mitchell; Weisenburger, Dennis; Greiner, Timothy; Gross, Thomas; and Chan, Wing, "Molecular distinctions
between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling"
(2012). Public Health Resources. 145.
https://digitalcommons.unl.edu/publichealthresources/145

This Article is brought to you for free and open access by the Public Health Resources at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by
an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Karen Deffenbacher, Javeed Iqbal, Warren Sanger, Yulei Shen, Cynthia Lachel, Zhongfeng Liu, Yanyan Liu,
Megan Lim, Sherrie Perkins, Kai Fu, Lynette Smith, James Lynch, Louis Staudt, Lisa M. Rimsza, Elaine
Jaffe, Andreas Rosenwald, German Ott, Jan Delabie, Elias Campo, Randy Gascoyne, Mitchell Cairo, Dennis
Weisenburger, Timothy Greiner, Thomas Gross, and Wing Chan

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/145

LYMPHOID NEOPLASIA

Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin
lymphomas identified through genomic profiling
*Karen E. Deffenbacher,1 *Javeed Iqbal,1 Warren Sanger,2 Yulei Shen,1 Cynthia Lachel,1 Zhongfeng Liu,1 Yanyan Liu,1
Megan S. Lim,3 Sherrie L. Perkins,4 Kai Fu,1 Lynette Smith,5 James Lynch,5 Louis M. Staudt,6 Lisa M. Rimsza,7 Elaine Jaffe,8
Andreas Rosenwald,9 German K. Ott,10 Jan Delabie,11 Elias Campo,12 Randy D. Gascoyne,13 Mitchell S. Cairo,14
Dennis D. Weisenburger,1 Timothy C. Greiner,1 Thomas G. Gross,15 and Wing C. Chan1
1Department

of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE; 2Munroe-Meyer Institute, University of Nebraska Medical
Center, Omaha, NE; 3Department of Pathology, University of Michigan Health System, Ann Arbor, MI; 4Department of Pathology, University of Utah, Salt Lake
City, UT; 5Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE; 6Metabolism Branch, Center for Cancer Research, National Cancer
Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; 7Department of Pathology, University of Arizona, Tucson, AZ; 8Laboratory of Pathology, Center
for Cancer Research, NCI, NIH, Bethesda, MD; 9Department of Pathology, University of Wurzburg, Wurzburg, Germany; 10Department of Clinical Pathology,
Robert-Bosch-Hospital, Stuttgart, Germany; 11Department of Pathology, Norwegian Radium Hospital, University of Oslo, Oslo, Norway; 12Hospital Clinics,
University of Barcelona, Barcelona, Spain; 13Departments of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Centre for Lymphoid
Cancers, Vancouver, BC; 14Departments of Pediatrics, Medicine, Pathology, and Cell Biology, Columbia University, New York, NY; and 15Section of
Hematology/Oncology/Blood and Marrow Transplant, Nationwide Children’s Hospital, Columbus, OH

Burkitt lymphoma (BL) predominates in
pediatric patients, whereas diffuse large
B-cell lymphoma (DLBCL) is uncommon.
In contrast to adults, BL and DLBCL are
treated similarly in children and both entities have superior outcomes in children
compared with adults. Gene expression
profiling (GEP) and miRNA expression
profiling clearly differentiated pediatric
DLBCL from BL, forming distinct clusters
regardless of patient age. However, pathway analysis of GEP data identified minor
differences between corresponding pedi-

atric and adult tumors. Predominance
(6:1) of the germinal center B-cell subtype
to activated B-cell subtype was found
among pediatric DLBCL. Two cases were
molecularly classified as primary mediastinal B-cell lymphoma. We observed frequent abnormalities in 8q24 in pediatric
DLBCL, including MYC rearrangement in
31% (5 of 16) and gain or amplification in
50% (6 of 12) nonrearranged cases. MYC
rearrangement was present in 96% (23 of
24) BL cases. Array-based CGH analysis
identified abnormalities that are shared

between adult and pediatric DLBCL
(ⴙ12q15, ⴙ19q13, ⴚ6q), and abnormalities unique to the pediatric cases (ⴚ4p14,
ⴚ19q13.32, ⴙ16p11.2), suggesting distinct pathogenetic mechanisms relative
to age. Elucidation of the underlying target genes may provide insight into factors that modulate outcome and could
provide potential novel therapeutic targets with less toxicity for pediatric patients with B-cell non-Hodgkin lymphoma.
(Blood. 2012;119(16):3757-3766)

Introduction
Lymphoma is the third most frequent type of cancer in children,
accounting for approximately 15% of childhood malignancy. The
incidence of lymphoma varies from only 3% in children younger
than 5 years to 24% in 15 to 19 year olds.1-3 In children,
non-Hodgkin lymphoma (NHL) consists predominantly of mature
aggressive B-cell lymphomas, with Burkitt lymphoma (BL) being
most common in 5 to 14 year olds and diffuse large B-cell
lymphoma (DLBCL) predominating in 15 to 19 year olds.1,3
Pediatric BL and DLBCL are treated uniformly with short but
high-intensity multiagent chemotherapy regimens designed for BL.
Both entities have superior outcomes relative to adults, with overall
survival (OS) rates greater than 90%.1,4-8 Despite these advances,
intensive chemotherapy is associated with significant morbidity,
and more targeted, pathway-specific therapeutic approaches are
desirable.8,9 Although adult BL is also treated with a high-intensity
regimen, adult DLBCL is treated with R-CHOP or CHOP-like
regimens.10,11 The prognosis of adult DLBCL remains significantly
worse than DLBCL in children, but it is unclear whether this is

because of the ability of children to better tolerate intensive
treatment or whether distinct pathogenetic mechanisms modulate
disease outcome.
BL and DLBCL are recognized by the World Health Organization (WHO) as separate entities having distinct genetic alterations,
tumor morphology, and immunophenotype. However, there is
significant overlap in the defining features of BL and DLBCL in
some cases, resulting in a group of unclassifiable lymphomas with
features intermediate between BL and DLBCL.12 Compared with
adults, pediatric DLBCL shares more features with BL, including
high proliferation, increased MYC expression, decreased BCL2
expression, higher incidence of MYC translocation, and germinal
center (GC) phenotype (75%).13,14 Delineation of homogeneous
groups of BL and DLBCL to help identify tumor-specific characteristics therefore remains challenging. Gene expression profiling
(GEP) has been used to more precisely classify BL and DLBCL
molecularly.15,16 Using GEP-defined groups of molecular BL
(mBL), 2 previous studies found no differences in gene expression
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or DNA copy number alterations (CNAs) between pediatric and
adult mBL, despite clinical differences between these 2 groups.17-19
Comparisons of GEP and CNA between adult and pediatric
DLBCL has not been reported, however.
Genome-wide miRNA profiling has also been used to molecularly define different types of lymphoma. Using 6 BL cases, 1 study
identified miRNAs differentially expressed in BL relative to
chronic lymphocytic leukemia, mantle cell lymphoma, and follicular lymphoma.20 A 9-miRNA signature was also found to differentiate the activated B-cell (ABC) and GC B-cell (GCB) subtypes of
DLBCL.21 Through coordination of array CGH and miRNA
expression data, Li et al identified 63 miRNA that are deregulated
in DLBCL by recurrent copy number (CN) changes.22 These
studies underscore the contribution of miRNA deregulation in
lymphoma pathogenesis and the potential utility of miRNA profiling in classifying tumors. However, miRNA profiles that distinguish BL and DLBCL are still unavailable, and profiling of
pediatric lymphomas has not been reported.
DLBCL is a heterogeneous group of entities both clinically and
biologically, and includes the GCB and ABC subtypes, which can
be defined molecularly by GEP.23-25 After multiagent chemotherapy, with or without rituximab, patients with the GCB subtype
have a significantly better OS compared with those with the ABC
subtype.23,26 Primary mediastinal large B-cell lymphoma (PMBL)
shares morphologic features with DLBCL but is now recognized as
a distinct entity that shares some features of classical Hodgkin
lymphoma.27 In contrast with other DLBCL subtypes, therapeutic
outcomes are worse for children with PMBL compared with adult
patients.28,29 By immunohistochemistry, pediatric DLBCL was
shown to consist predominantly of the GCB subtype,13,14 which
may account for the favorable prognosis in this age group.
However, a GEP-based molecular classification of pediatric
DLBCL is currently lacking.
In this study, we sought to characterize pediatric BL and
DLBCL molecularly using GEP and miRNA analysis, and to
determine whether differences in these signatures exist between
pediatric and adult tumors. Using homogeneous, molecularly
defined cohorts, we also examined whether differences in genetic
alterations or molecular pathways between adult and pediatric
tumors may explain the clinical differences and provide insight into
distinct pathogenetic mechanisms.

GEP
Frozen sections were cut from each of the cryopreserved blocks and
examined for adequacy of the materials before other studies. Genomic
DNA and total RNA were isolated by All prep DNA/RNA Mini Kit
(QIAGEN). GEP was done by Human Genome U133 Plus Version 2.0 array
(Affymetrix) and analyzed by BRB-ArrayTools Version 3.7 software
(http://linus.nci.nih.gov/BRB-ArrayTools.html),30 as previously described.23
Molecular classification of cases was by the Bayesian compound covariate
predictor method25 using a published gene expression signature distinguishing BL from DLBCL,15 as described previously.31 A second published gene
signature that distinguishes mBL from other mature aggressive B-cell
lymphomas16 was used to confirm the BL and DLBCL molecular classifications. Cases classified as molecular DLBCL were then subclassified into
ABC, GCB, and PMBL subtypes of DLBCL.23,27 Gene set enrichment
analysis was used to compare pediatric (n ⫽ 45) with adult (n ⫽ 17) mBL,
and pediatric (n ⫽ 13) with adult (n ⫽ 51) GCB mDLBCL using the
Curated Gene Set in the Broad Institute’s Molecular Signature Database.
SNP array analysis of DNA CNAs and copy neutral LOH
Genomic DNA (250 ng) was prepared from all 21 pediatric mDLBCL
specimens according to the GeneChip Mapping 500K Assay protocol for
hybridization on 250K NspI Human Mapping Arrays (Affymetrix). Single
nucleotide polymorphism (SNP) genotypes, CN data, and regions of copy
neutral loss of heterozygosity (LOH) were generated using Genotyping
Console Version 2.1 software from Affymetrix, as previously described.31
CNAs were aligned and the minimal common region (MCR) for each
recurrent abnormality was determined. CNA occurring in more than 10% of
cases were selected for further analysis. MCRs that were devoid of genes or
that showed complete overlap with an annotated CNV of similar CN state
were excluded. Gene expression data for all RefSeq genes residing in an
MCR were compared with gene CN using the class comparison tool in BRB
ArrayTools. The criterion used to define differential gene expression
between CNA⫹ and CNA⫺ groups was P ⬍ .05 under the random variance
model univariate test.
Analysis for MYC gene rearrangement
Interphase FISH analysis for chromosome 8q24 (MYC) translocations was
performed using cryostat tissue sections, as previously described with
minor modification.32 Briefly, a MYC break-apart probe (Abbott-Vysis) was
used for hybridization. Nuclei were counterstained with 4,6-diamidino-2phenylindole in Antifade solution, and the slides were visualized using an
Olympus BX51 fluorescence microscope. Images were captured and
archived using CytoVision Version 4.5.2 software (Applied Imaging). A
total of 50 to 100 nuclei per case were scored for the presence of the MYC
translocation. The normal cutoff for this FISH assay in tissue sections has
been established to be 15% by prior studies.

Methods

miRNA isolation and profiling

Patient characteristics

Total RNA for miRNA profiling was extracted from four 20M sections
(based on 1 cm2 surface area) of cryopreserved tissues using the mirVana
miRNA isolation Kit according to the manufacturer’s instructions (Ambion). Reverse transcription was done with 300 ng of total RNA using the
Megaplex RT Primers and enzyme kit as suggested by the manufacturer
(ABI). To enhance assay sensitivity, a preamplification step of 12 cycles
was introduced using Megaplex PreAmp Primers. The preamplified cDNA
was loaded onto the 384-well format TaqMan microRNA assay plates
(TaqMan human miRNA array Version 2.0, ABI). Quantitative real-time
PCR was performed on a 7900HT Fast Real-Time PCR System (ABI).
Threshold cycle (CT) was defined as the fractional cycle number at which
the fluorescence exceeds the fixed threshold of 0.1 with automatic baseline
using the RQ Manager Version 1.2 software (ABI). The raw data were
uploaded into BRB-ArrayTools (Version 3.7.0) for analysis. Using the
expression of all miRNA, classification of BL and DLBCL cases was done
using the compound covariate Bayesian predictor, in which specimen labels
were assigned by the GEP-based molecular classifier. Classification precisions were evaluated using leave-one-out cross-validation. Differential

Pediatric specimens were collected from the Cooperative Human Tissue
Network pediatric NHL repository through the Children’s Oncology Group,
and adult specimens were collected from the Nebraska Lymphoma Study
Group Registry and Tissue Bank. Pediatric patients were defined using a
cut-off of 20 years of age or younger and adult patients were defined as
older than 20 years. Frozen tissues were obtained from 57 pediatric BL
(ages 2-20 years; median, 8 years), 13 pediatric DLBCL (ages 9-18 years;
median, 15 years), 26 adult BL (ages 21-85 years; median, 66 years), and
98 adult DLBCL (ages 22-87 years; median, 60 years). Clinical data were
available on all adult and 36 pediatric patients. Pathology review of the
pediatric cases was done by T.C.G. and W.C.C. using available materials,
which included institutional pathology reports and hematoxylin and eosin
slides, and adult cases were reviewed by a panel of Leukemia/Lymphoma
Molecular Profiling Project pathologists. GEP was done on all pediatric
(n ⫽ 70) and adult (n ⫽ 124) cases. This study was reviewed and approved
by the institutional review board at University of Nebraska Medical Center.
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Table 1. Classification of pediatric patients
Pathologic diagnosis
Median age at diagnosis, y (range)

BL (n ⴝ 57)

DLBCL (n ⴝ 13)

8 (2-20)

15 (9-18)

Sex
Female

11

3

Male

46

10

Molecular diagnosis*
mBL

45

mDLBCL

10†

11

2

0

NC

2†

NC indicates nonclassifiable cases with a diagnostic probability of ⬍ 90% by
Bayesian classification.
*Molecular diagnosis is the Bayesian classification of cases using the Burkitt
Lymphoma Gene Signature derived from Dave et al.15
†Case with a molecular classification that was discrepant with the pathologic
diagnosis.

miRNA expression between groups was determined by random-variance
T test and significance-analysis-of-microarrays (SAM).
Clinical correlations
Fisher exact test was used to analyze categorical data, and Wilcoxon
rank-sum test was used to analyze continuous data between groups. Fisher
exact test was used to examine the association between age and GEP
predictor in DLBCL. Posthoc tests were adjusted for multiple comparisons
using the Bonferroni method. The Kaplan-Meier method was used to
estimate overall survival distributions, and the log-rank test was used to
compare survival distributions between groups. SAS Version 9.3 software
was used for data analysis (SAS Institute).
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identified 47 mBLs and 21 mDLBCLs with probability more than
99% (Table 1; Figure 1A). Two cases had probabilities intermediate
between BL and DLBCL and were not classifiable molecularly.
Approximately 80% of all pediatric cases had a molecular classification consistent with the pathologic diagnosis; however,
10 morphologically defined BLs were reclassified as mDLBCL and
2 morphologically defined DLBCLs were reclassified as mBL. To
confirm the case reclassifications, we used a second, independently
derived gene signature that distinguishes mBL from other mature
aggressive B-NHL.16 Cases classified as mBL or mDLBCL were
concordant between the 2 gene signatures; however, a higher
number of cases were unclassifiable (ie, probability ⬍ 90%) by
Hummel classifier,16 with the majority of these cases showing
probability of more than 70% versus more than 90% by our
classifier for the same entity.15
Subtype classification of the 21 pediatric mDLBCL specimens
was done using 2 gene signatures: a predictor that distinguishes
GCB and ABC subtypes,23 and a PMBL gene signature.27 These
classifiers identified 13 GCB, 2 ABC, 2 PMBL, and 4 nonclassifiable cases (Table 2). Both PMBL cases were female adolescents
with a mediastinal mass and amplification of the chromosome 2p
REL locus, as detected by array comparative genomic hybridization. A higher proportion of the GCB subtype relative to the ABC
subtype was found, predominantly in the discrepant cases (ie, those
classified as BL by pathology and mDLBCL by GEP). The
supervised hierarchical clustering of all pediatric and adult cases
showed 2 distinct clusters of BL and DLBCL patients regardless of
patient age (Figure 1B). The pediatric and adult cases intermixed
and did not form subclusters, suggesting strong similarity of the
respective pediatric and adult tumors at the gene expression level.

Results
Patient characteristics and molecular classification

Table 1 summarizes the pathologic and molecular classifications
and characteristics of the 70 pediatric patients. The 57 pediatric BL
patients, as determined by pathology, were predominantly male
(⬎ 80%) and had a median age at diagnosis of 8 years. The
13 pediatric DLBCL patients by pathology were also mostly male
and had a median age at diagnosis of 15 years, which was
significantly different from the BL median age (P ⬍ 5 ⫻ 10⫺5). For
patients with a concordant molecular and pathologic diagnosis,
median age at diagnosis was 8 years for mBL and 15 years for
mDLBCL. However, mBL cases with a discrepant DLBCL pathologic diagnosis had a median age at diagnosis of 13 years,
significantly different from other mBL (P ⫽ .02). Similarly, mDLBCLs with discrepant BL pathology had a median age at diagnosis
of 6 years, significantly different from other mDLBCLs (P ⫽ .0001).
Supplemental Figure 1 (available on the Blood Web site; see the
Supplemental Materials link at the top of the online article)
illustrates the significant differences in OS between pediatric and
adult cases defined molecularly by GEP. Pediatric DLBCL and BL
had OS of 100% and 90%, respectively. As expected, adult
DLBCL, whether treated with CHOP or R-CHOP, and adult BL
treated aggressively had a significantly decreased OS relative to the
pediatric cases.6 Five cases of DLBCL from the Nebraska Lymphoma Study Group Registry and Tissue Bank were younger than
20 years but were treated with a CHOP-like regimen similar to
adult DLBCL. Interestingly, these cases had a better OS relative to
adult DLBCL patients who were treated similarly.
Using the Bayesian prediction method, we applied a GEP-based
molecular classifier to the pediatric cases that robustly distinguishes BL and DLBCL in adult lymphomas.15 The predictor

Differential gene expression and pathway enrichment in adult
and pediatric lymphomas

Using molecular classification, a sufficient number of pediatric
GCB mDLBCL (n ⫽ 13) and mBL (n ⫽ 45) cases were available
for comparison with adult GCB mDLBCL (n ⫽ 51) and adult mBL
(n ⫽ 17) cases. SAM analysis identified only 132 differentially
expressed genes between adult and pediatric GCB mDLBCL
(supplemental Table 1; supplemental Figure 2) and 63 differentially
expressed genes between adult and pediatric mBL (supplemental
Table 2; supplemental Figure 3). Gene set enrichment analysis
identified pathways and gene signatures that differed significantly
between pediatric and adult tumors (Table 3). Comparison of adult
and pediatric GCB mDLBCL revealed enrichment for B-cell
surface molecules and GC markers in adult GCB cases. Genes
within these pathways that were up-regulated in adult GCB relative
to pediatric GCB included CD19, CD20, CD40, CD52, CD72,
CD79a, CD79b, CXCR5, and BLNK. Ingenuity analysis found
Table 2. Molecular subtype classification of pediatric DLBCL
Molecular diagnosis†
Pathologic diagnosis*

GCB

ABC

PMBL

NC

DLBCL

5

1

2

3

BL

8

1

0

1

13

2

2

4

Total

NC indicates nonclassifiable cases with a diagnostic probability of ⬍ 90% by
Bayesian classification.
*Pathologic diagnosis is the specimen diagnosis based on pathology review
provided by the Cooperative Human Tissue Network.
†Molecular diagnosis is the Bayesian classification of cases using 2 DLBCL
subtype gene signatures: 1 that distinguishes GCB and ABC DLBCL subtypes,23 and
a PMBL gene signature.27
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Figure 1. Gene expression profiling of BL and DLBCL. (A) Molecular classification of pediatric lymphomas using the Bayesian compound covariate predictor method and a
published gene signature that distinguishes BL from DLBCL.15 GEPs of adult lymphomas used to derive this signature were used as a training (GEO accession no. GSE4732)

BLOOD, 19 APRIL 2012 䡠 VOLUME 119, NUMBER 16

further enrichment for pathways involved in inflammation and
altered T- and B-cell signaling in adult relative to pediatric GCB
mDLBCL. Enrichment for apoptosis pathways, BCR signaling,
and GC markers, G1 to S cell cycle transition, BCL2 family, and
PIP3, p38 MAPK, and IL-10 signaling pathways were found in
adult mBL relative to pediatric mBL. Interestingly, p38 MAPK
signaling has been shown to up-regulate IL-10 gene expression in
BL cells, in turn promoting lymphomagenesis.33 In contrast,
pediatric mBL showed enrichment for inflammatory pathways and
MYC targets relative to adult mBL tumors.
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Table 3. Differential pathway and gene set enrichment in adult and
pediatric tumors
Broad GeneSets

No. of
genes

P (Goeman
global test)

Enrichment in Adult mGCB relative to Ped mGCB
BASSO_GERMINAL_CENTER_CD40_UP

225

.023

TH1 TH2 PATHWAY

28

.009

CELL_CYCLE_CHECKPOINT_II

21

.022

CTLA4 PATHWAY

41

.009

TARTE_BCELL

71

.024

Enrichment in Adult mBL relative to Ped mBL

miRNA profiling

APOPTOSIS_KEGG

118

.0003

BRENTANI_DEATH

176

.002

Expression profiles of 380 miRNAs were generated from a
representative sample of 46 adult mDLBCL, 12 pediatric mDLBCL, 13 adult mBL, and 18 pediatric mBL specimens that were
selected based on gene expression-defined molecular classification.
Comparison of mBLs and mDLBCLs identified 35 differentially
expressed miRNAs (supplemental Table 3). The 35 miRNA
signature identified by SAM analysis included 15 miRNAs highly
expressed in mBLs relative to mDLBCLs (BL signature), and
20 miRNA highly expressed in mDLBCLs relative to mBLs
(DLBCL signature). The BL signature is dominated by MYCregulated miRNAs, including the miR-17-92 cluster, along with the
paralogous cluster on the X chromosome (miR-18b, miR-20b, and
miR-106a). A subset of mDLBCL cases (20 of 58) showed high
expression of the BL miRNA signature, suggesting high MYC or
E2F activity. Hierarchical clustering of these 35 miRNAs segregated BL and DLBCL into 2 major distinct clusters, with each
cluster containing an admixture of both pediatric and adult mBL or
mDLBCL cases (Figure 1C). Of 89 cases, only 2 adult DLBCLs
clustered with the BL cases and only one pediatric BL clustered
with DLBCL cases, confirming that these are 2 distinct entities
regardless of patient age. A subset of DLBCL cases, both pediatric
and adult, expressed high levels of both the DLBCL and BL
miRNA signatures, forming a distinct cluster of DLBCLs at the far
right of Figure 1C. Comparison of miRNA expression between
pediatric and adult tumors by SAM analysis (FDR ⫽ 0.1) revealed
no significant differences in DLBCL and only a single significant
miRNA in BL, whereby miR-9 expression was 5-fold lower in
pediatric BL relative to adult BL.

APOPTOSIS_GENMAPP

MYC gene rearrangement analysis

FISH analysis was performed on all molecularly reclassified and
concordant DLBCL cases that we had sufficient materials for
examination. The results are shown in Table 4. Of the concordant
cases, one of 7 had MYC rearrangement, whereas the discordant
cases showed 4 of 9 evaluable cases with rearrangement. Gain or
amplification affecting the MYC locus was frequent, affecting 3 of
5 concordant and 3 of 6 discordant cases without MYC rearrangement. Gain of chromosome 8 is rare in BL and pediatric
DLBCL,19,34 indicating that these changes were not the result of
whole chromosome gains. Thus, abnormalities of the MYC locus
were frequent in these pediatric DLBCL cases with rearrangement
in a total of 5 of 16 and gain or amplification in 6 of 11
nonrearranged cases. FISH and cytogenetic studies were performed
on 26 cases of BL with 24 cases having evaluable results. Of these,

APOPTOSIS

99

.001

168

.001

CASPASE PATHWAY

54

.0005

SA_FAS_SIGNALING

27

.002

DEATH PATHWAY

86

.002

BAD PATHWAY

60

.004

104

.009

P38 MAPK PATHWAY
ST_P38_MAPK_PATHWAY

99

.02

IL10 PATHWAY

31

.001

IL18 PATHWAY

10

.001

RAS PATHWAY

53

.016

AKT PATHWAY

32

.026

ST_JAK_STAT_PATHWAY

23

.003

115

.007

KIM_TH_CELLS_UP
ST_TUMOR_NECROSIS_FACTOR_PATHWAY

67

.009

G1_TO_S_CELL_CYCLE_REACTOME

142

.008

SIG_BCR_SIGNALING_PATHWAY

139

.005

BCR PATHWAY

98

.019

SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES

97

.003

225

.004

BASSO_GERMINAL_CENTER_CD40_UP
Enrichment in Pediatric mBL relative to Adult mBL
INFLAMMATORY_RESPONSE_PATHWAY
MYC_TARGETS

70

.002

109

.0006

23 cases (96%) had MYC rearrangement. The remaining case
showed amplification of the 8q24 locus.
Chromosomal imbalances in pediatric lymphoma

High-quality SNP data (SNP call rate ⱖ 85) for DNA CN analysis
were obtained from 18 of 21 pediatric cases of mDLBCL,
including 11 GCB, 2 ABC, 2 PMBL, and 3 nonclassifiable
mDLBCL (mDLBCL-NC). To determine the spectrum of CNAs in
pediatric DLBCL, MCRs were compiled for aberrations occurring
in 2 or more cases and included 16 recurrent gains (Figure 2A) and
18 recurrent losses (Figure 2B). Supplemental Figure 2 illustrates
the genome wide aberrations for pediatric mDLBCL cases, coded
by molecular subtype. Both PMBL cases harbored a gain of 2p that
included the REL and BCL11A genes. Large aberrations previously
found in DLBCL34,35 were also observed in the pediatric cases,
including: 6q⫺, ⫹7/7q⫹, ⫹12, 17p⫺, and 17q⫹ (supplemental
Figure 2). Losses of 19q13.32 and 4p14 minimal regions are novel
and have not been reported in other DLBCL series. Recurrent
regions of copy neutral LOH were also observed at 1q, 2, 6p, 9p,
and 19p.

Figure 1 (continued) dataset for the Bayesian predictor. Pediatric lymphomas with a probability ⱖ 90% were classified accordingly. (B) Hierarchical clustering of adult
(n ⫽ 21) and pediatric (n ⫽ 49) BL and adult (n ⫽ 102) and pediatric (n ⫽ 21) DLBCL cases using the gene expression signature used in panel A demonstrated robust
distinction of BL and DLBCL regardless of patient age. Pediatric and adult specimens intermingled and did not form distinct subclusters. (C) Hierarchical clustering of BL and
DLBCL using 35 significantly differentially expressed miRNAs between BL and DLBCL. Cases clustered by entity regardless of patient age. Two adult DLBCL cases clustered
with BL and one pediatric BL case clustered with DLBCL. A separate cluster of DLBCL (far right) demonstrated high expression of both the BL and DLBCL signatures.
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Table 4. Myc rearrangement and gain/amplification in pediatric DLBCL
Molecular diagnosis by GEP
Case ID

Pathologic diagnosis

BL vs DLBCL

DLBCL subgroup

Age, y

Sex

t(8;14)

8q24 CN

P01

DLBCL

DLBCL

GCB

9

M

⫺

3-4

P02

DLBCL

DLBCL

GCB

10

M

⫺

3-5

P03

DLBCL

DLBCL

GCB

13

M

⫺

3-4

P04

DLBCL

DLBCL

GCB

18

F

⫺

ND

P05

DLBCL

DLBCL

PMBL

15

F

⫺

2

P06

DLBCL

DLBCL

UC

11

M

⫺

2

P07

DLBCL

DLBCL

UC

18

M

⫹

3-4

P08

BL

DLBCL

ABC

2

P09

BL

DLBCL

UC

P10

BL

DLBCL

GCB

P11

BL

DLBCL

GCB

P12

BL

DLBCL

GCB

P13

BL

DLBCL

GCB

P14

BL

DLBCL

P15

BL

DLBCL

P16

BL

P17

BL

2

M

⫹

11

F

⫹

3

6

M

⫹

ND

4

F

⫹

2

10

M

⫺

2

10

F

⫺

3-4

GCB

2

M

⫺

2

GCB

5

M

⫺

3

DLBCL

GCB

6

M

ND

Amplification

DLBCL

GCB

12

M

⫺

ND

The abnormal range for MYC rearrangement is 15%-100%. The abnormal range for MYC amplification is 10%-100%. The abnormal range for multiple copies of 8q24 is
10%-100%.
UC indicates unclassifiable DLBCL; and ND, not determined.

Supplemental Table 4 lists all RefSeq genes residing within
each minimal region. Genes highlighted in bold demonstrated
significant correlation between DNA CN and gene expression.
However, because of small sample size and the heterogeneous
groups of cases, only a small number of genes showed clear
correlation of expression with gene CN. Extended MCRs, which
included an additional 1 Mb on either side of the minimal region,
were also examined. Table 5 lists candidate genes for select
extended MCRs based on putative gene/protein function and/or
correlation of gene expression with DNA CN (bolded genes).

Discussion
In this study, we performed molecular profiling of a cohort of
pediatric aggressive B-cell NHLs, including 57 BL and 13 DLBCL
defined by morphology. Pediatric patients with NHL have a
significantly better prognosis than adult patients with the same
histologic subtype,8 a finding that was also observed in this study
(supplemental Figure 1). Between the ages of 15 and 29 years, the
predominant histologic subtype shifts from BL to DLBCL, transitioning from a childhood to an adult NHL spectrum.1,3 Despite this
shift in incidence, adolescent DLBCL patients in the 15- to 20-year
age range fare better when treated with more aggressive regimens.4,7 Accordingly, 5 DLBCL cases within the 15- to 20-year age
range in this study had been treated similar to adult DLBCL
patients, receiving a CHOP-like regimen, and showed significantly
decreased OS relative to pediatric DLBCL receiving aggressive
therapy (supplemental Figure 1). Additional cases need to be
studied to discern whether this reflects a true change in biology or
merely a better prognosis with younger age and more aggressive
treatment.
Identifying a homogeneous patient population is important in
studying underlying tumor biology, yet the distinction between BL
and DLBCL remains a diagnostic challenge. The 2008 WHO
classification includes a provisional category of B-cell lymphoma,
unclassifiable, with features intermediate between DLBCL and BL,
to account for the significant number of cases with morphologic,

immunophenotypic and cytogenetic features intermediate between
BL and DLBCL.12 In contrast to adults, pediatric DLBCL have
been reported to demonstrate moderate to high proliferation rates
(83%), increased MYC protein expression (84%), a higher incidence of MYC translocation (37%),36 and an increased frequency of
the GC phenotype (75%), suggesting greater similarity between the
molecular features of DLBCL and BL in pediatric cases.13 GEP has
been used to more precisely classify BL and DLBCL both in
adults15,16,37 and children.17-19,34 Using our molecular signatures to
distinguish BL and DLBCL, we observed an approximate 20%
reclassification rate for both morphologic BL (10 of 57 mDLBCL)
and DLBCL (2 of 13 mBL). We also examined our cases with the
Hummel classifier,16 and cases classified as mBL or mDLBCL are
in complete concordance with our cases, but there are more
unclassifiable cases using their classifier. The relatively high rate of
reclassification for childhood cases may be the result of an increase
in cases with overlapping features in pediatric BL and DLBCL,
particularly the higher incidence of MYC deregulation and increased proliferation in childhood DLBCL. MYC rearrangement
studies indeed demonstrated a higher incidence of rearrangement in
childhood DLBCL than adult cases, consistent with Poirel et al,34
findings that showed Myc rearrangement in 33% of pediatric
DLBCLs.34 In addition, there was also a high incidence of gain or
amplification in the MYC locus supporting that deregulated expression of the MYC gene may be a prominent feature of pediatric
DLBCL. The study of pediatric DLBCL and BL by Klapper et al
reclassified a large number of cases, but there was more reclassification of DLBCL into mBL than in the reverse direction.17 There
was also a lower incidence of MYC rearrangement in the mDLBCL
cases. The differences with our series could be partly the result of
the different tendency of classification by pathologists of the
2 tumors in the United States. The incidence of MYC rearrangement
is higher in our mDLBCL cases, which may be partly related to the
limitations inherent to the rather small number of cases in both
series. There were also a larger number of unclassifiable cases in
the series by Klapper et al,17 and some of these cases could have
been classified into a specific category by our diagnostic algorithm.
These issues need to be addressed in the future by studying a large series

BLOOD, 19 APRIL 2012 䡠 VOLUME 119, NUMBER 16

GENOMIC PROFILING OF PEDIATRIC B-CELL LYMPHOMA

3763

Figure 2. Pediatric mDLBCL DNA copy number alterations. Recurrent DNA CN gains (A) and losses (B) detected by array CGH in molecularly defined pediatric DLBCL.
The cytoband is listed for each MCR occurring in 2 or more patient samples. Frequency of aberration is coded according to the molecular subtype classification.

of cases using uniform techniques and criteria. MYC gene was rearranged in the majority (96%) of mBL cases as expected. Similar
incidence has been observed in Poirel et al34 and Klapper et al.17
DLBCL cases reclassified as molecular BL showed high
expression of MYC and MYC targets, high expression of “BL-high”
GCB genes,15 and low expression of MHC-I and NF-B target
genes. Unsupervised hierarchical clustering divided mBL and
mDLBCL cases into 2 distinct clusters, providing further support
for these classifications. Pediatric and adult cases were intermixed,
demonstrating significant overlapping features within each entity
regardless of patient age. These data show that molecular classification provides a robust means of diagnosing BL and DLBCL,
particularly in pediatric cases.
By immunohistochemical classification, pediatric DLBCL cases
show a predominance of the GCB subtype; however, unlike adult
GCB DLBCL, the t(14;18) translocation is reported to be rare or
absent.13,14 In a subsequent study, Klapper et al were not able to
demonstrate the predominance of the GCB subtype in their series
of DLBCL,17 but, using a GEP signature that distinguishes the
GCB and ABC subtypes of DLBCL,23 we found a 3:1 predominance of the GCB subtype in pediatric mDLBCL by gene

expression. However, too few cases were available to ascertain
whether the GCB subtype predominance accounts for the favorable
outcome in pediatric relative to adult DLBCL. Two female
pediatric PMBL cases were also identified using a gene signature
that distinguishes PMBL from the other DLBCL subtypes.27
Amplification of the REL locus is frequently seen in PMBL38 and
was found in both pediatric cases by array comparative genomic
hybridization.
Comparative analysis of the GEP of childhood and adult
DLBCL has not previously been undertaken. A sufficient number of
pediatric GCB cases (n ⫽ 13) were available in this study for
comparison with adult GCB mDLBCL. At the gene expression
level, pediatric and adult GCB DLBCL were highly homogeneous,
differing in only 132 transcripts by SAM analysis (supplemental
Table 1). Pathway analysis revealed enrichment in expression of
B-cell surface molecules, genes involved in BCR signaling, and
altered T- and B-cell signaling pathways in adult relative to
pediatric GCB DLBCL. Enhanced antigen-independent B-cell
signaling and/or pathway alterations, which facilitate tonic BCR
signaling, may be important in B-cell survival in adult DLBCL.
Pediatric DLBCL may be less dependent on BCR signaling,
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Table 5. Locus-specific impact of DNA CN on gene expression for candidate genes within select MCRs
Cytoband

Locus description

Genes*

Gains
1q21.1

MCL1

OTUD7B

PIAS3

BCL9

NOTCH2NL

ACTR2

PELI1

SLC1A4

REL

BCL11A

3q21.3

CNBP

GATA2

MCM2

PIK3R4

3q27.3

BCL6

RFC4

ST6GAL1

TBCCD1

11q13.1

BBS1

ANKRD13D

RELA

2p15

Amplified in PMBL35

ZNHIT2

CCND1

12q15

Adult GCB35

FRS2

RAB3IP

IFNG

MDM1

MDM2

16p11.2

Novel in pediatric DLBCL

FUS

MAZ

BCL7C

CD19

NFATC2IP

19q13.2

Adult ABC35

AKT2

LYPD4

PAK4

CD79A

NFKBIB

SEPT10

BCL2L11

Losses
2q13
4p14

Novel in pediatric DLBCL

APBB2

RHOH

TLR1/6/10

6q21

Adult ABC35

ATG5

AIM1

FOXO3

LIN28B

PRDM1

6q23.3

HBS1L

BCLAF1

PERP

IFNGR1

TNFAIP3

12q24.31

RHOF

BCL7A

DIABLO

16p11.2

TAOK2

NFATC2IP

BCL7C

CD19

TP53TG3

19p13.3

RFX2

EBI3

TNFAIP8L1

TNFSF14

TNFSF9

BAX

BBC3

BCL3

IRF2BP1

19q13.32

Novel in pediatric DLBCL

*Genes highlighted in bold showed a significant correlation between gene expression and gene CN. Locus description annotates MCR in the pediatric cases that were
either novel or that have been previously reported to be enriched in specific DLBCL subtypes.

suggesting alterations in pathways that compensate for this.
FOXO1-dependent PI3K signaling, downstream of the BCR, was
recently shown to promote survival of BCR-deficient mature
B cells.39 In GCB DLBCL, constitutive or “tonic” BCR survival
signals through BCL6 in the absence of receptor stimulation have
been shown.40,41 Further studies on BCR signaling in pediatric
DLBCL would be of interest, as too few pediatric cases were
available in the present study to ascertain preferential activation of
PI3K or the alternative NF-B pathways in pediatric relative to
adult GCB DLBCL.
Genome-wide miRNA expression profiling demonstrated distinct expression profiles for mDLBCL and mBL patients. Pediatric
and adult cases, including the reclassified cases, were indistinguishable by miRNA expression profiling, further supporting the close
relationship between adult and pediatric tumors (Figure 1C).
One-third of mDLBCL cases also exhibited high expression of
many of the miRNA characteristically expressed by BL. Many of
these miRNAs are contributed by the miR17⬃92 cluster that is
up-regulated by MYC and certain other transcription factors, such
as E2F1.42 These may represent mDLBCL cases with higher
expression of MYC and/or other factors that up-regulate miR17⬃92.
Segregation of mDLBCL into distinct subgroups by miRNA
expression has been previously reported, with marked differences
in MYC-regulated miRNAs between groups.22 Consistent with
previous reports,20 a number of miRNAs prominently repressed in
mBL relative to mDLBCL were found, including miR-22, 23a, 29a,
29b, 29c, 34a, 125b, 150, 155, and 342. Some of these are known
MYC targets,43 and their repression is probably related to high
MYC activity. However, this group of miRNAs tends not to show
the marked repression, even in mDLBCL cases with moderate high
expression of miRs up-regulated in BL. It is possible that downregulating the MYC miRNA targets have different requirements
that are not present in the mDLBCL, so these miRs remain elevated
in these cases (MYC needs corepressors to repress gene expression
and inhibitors of MYC may also be present to modulate its
activities). In the DLBCL signature, many of the highly expressed
miRNAs were previously reported to be differentially expressed
between DLBCL and GCB cells, with high miR-222 expression
correlating with poor overall and progression-free survival.21 High

miR-125b expression may have functional relevance in DLBCL
through down-regulation of PRDM1 expression.21 Diminished
miR-155 expression in BL43 and elevated miR-155 expression in
DLBCL21 have been reported and were found to differentiate these
2 entities in the present study. Characterization of the targets of the
differentially expressed miRNAs may further aid in the classification of these 2 entities and in understanding the different biologies.
A second aim of this study was to identify genetic aberrations in
pediatric mDLBCL using high-resolution array comparative
genomic hybridization, and to compare these alterations with those
previously found in adult tumors because such a comparison has
not previously been reported. Poirel et al reported karyotype
abnormalities in pediatric DLBCL treated on the FAB LMB
96 trial.34 In that report, Poirel et al34 reported ⫹1q, del(13q), ⫹7q,
der(3q), der(9p), del(17p), der(18q), ⫹12q, der (11q), and del(6q),
in children and adolescents with DLBCL. Similarities with the
current array CGH study were demonstrated with losses at 3q and
6q and gains at 1q and 12q. However, the current array CGH study
was significantly more precise in identifying many more gains and
losses compared with the previous karyotype study in pediatric
DLBCL.34 Specific aberrations reported in adult DLBCL were also
found in the pediatric cases, including gain of the 2p15 REL locus
reported in PMBL; gain of 12q15, enriched in the GCB subtype of
adult DLBCL; and gain of 19q13.2 and loss of 6q21, enriched in
the ABC subtype of adult DLBCL.35 Our analysis was more
focused on the GCB subtype because it constitutes the majority of
pediatric DLBCL. Two novel deletions were found in the pediatric
cases: ⫺4p14 and ⫺19q13.32. The 19q13.32 locus harbors the
BAX and BBC3 tumor suppressor genes. Whereas deletion of
chromosome 4 and the 4p arm has been reported in lymphoma, a
minimal region has not been delineated. Deletion of 4p14 was
resolved to approximately 283 kb in this study. The RHOH gene in
this interval is expressed in T and B cells and is required for
lymphocyte receptor signaling.44 RHOH is also a target of aberrant
somatic hypermutation in B cells in DLBCL and other B-cell
leukemias and lymphomas.45 Expression of the APBB2 gene was
significantly diminished in the 4p14 deleted cases relative to
nondeleted cases. Consistent with a tumor suppressor role, APBB2
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is proapoptotic and a regulator of NF-B, p53, and WWOX,46
suggesting a potential functional role in lymphomagenesis.
There have been many discussions regarding the reasons
underlying the better prognosis of pediatric versus adult aggressive
B-cell lymphomas,3,32 be related to the intensive chemotherapy
regimens generally used in childhood cases, to age-related factors,
or to intrinsic differences in the biology between pediatric and adult
tumors. We have demonstrated the predominance of the GCB
subgroup in pediatric mDLBCL, which may partly explain the
better prognosis, in particular for tumors not expressing BCL2.47
Although pediatric BL and DLBCL were found to be similar at the
molecular level compared with the corresponding adult tumors, we
identified subtle differences in gene expression and genetic alterations in this study, suggesting underlying differences in tumor
biology between childhood and adult cases. Some genetic abnormalities seem to be unique to the pediatric mDLBCL (⫺4p14,
⫺19q13.32, ⫹16p11.2), and elucidation of the underlying target
genes may provide insight into factors that may modulate outcome.
However, we are uncertain of their significance in influencing
survival at this time. Further studies, such as next-generation
sequencing, may help to answer these important questions.
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Supplemental Table S1. Differentially Expressed Genes using SAM (FDR<0.1) between Pediatric (n = 13) and Adult (n = 51) GCB
DLBCL

Probe set
219753_at
238870_at

Fold-Change
Ped:Adult
-5.7
-5.4

Gene symbol

Description

STAG3
KCNK9

stromal antigen 3
potassium channel, subfamily K, member 9

217418_x_at

-5.0

MS4A1 (CD20)

membrane-spanning 4-domains, subfamily A, member 1

217818_s_at

-5.0

ARPC4

actin related protein 2/3 complex, subunit 4, 20kDa

206181_at

-3.9

SLAMF1

signaling lymphocytic activation molecule family member 1

214452_at

-3.7

BCAT1

branched chain aminotransferase 1, cytosolic

210895_s_at
228058_at

-3.7
-3.7

CD86
ZG16B

CD86 molecule
zymogen granule protein 16 homolog B (rat)

225723_at

-3.6

C6orf129

chromosome 6 open reading frame 129

223625_at

-3.6

FAM126A

family with sequence similarity 126, member A

228415_at

-3.5

AP1S2

adaptor-related protein complex 1, sigma 2 subunit

243364_at

-3.5

AUTS2

autism susceptibility candidate 2

200968_s_at
206513_at

-3.4
-3.3

PPIB
AIM2

peptidylprolyl isomerase B (cyclophilin B)
absent in melanoma 2

206348_s_at

-3.2

PDK3

pyruvate dehydrogenase kinase, isozyme 3

228116_at

-3.2

FLJ39632

hypothetical LOC642477

203007_x_at

-3.2

LYPLA1

lysophospholipase I

203470_s_at

-3.1

PLEK

pleckstrin

1560503_a_at

-3.1

LOC100130275

hypothetical protein LOC100130275

215674_at
202988_s_at

-3.1
-3.1

KIAA1659
RGS1

KIAA1659 protein
regulator of G-protein signaling 1

203923_s_at

-3.0

CYBB

cytochrome b-245, beta polypeptide

202961_s_at

-2.9

ATP5J2

ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2

205321_at

-2.9

EIF2S3

eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa

235777_at

-2.9

ANKRD44

ankyrin repeat domain 44

221058_s_at
212694_s_at

-2.9
-2.8

CKLF
PCCB

chemokine-like factor
propionyl Coenzyme A carboxylase, beta polypeptide

222699_s_at

-2.8

PLEKHF2

pleckstrin homology domain containing, family F (with FYVE domain) member 2

223158_s_at

-2.8

NEK6

NIMA (never in mitosis gene a)-related kinase 6

1558143_a_at

-2.8

BCL2L11

BCL2-like 11 (apoptosis facilitator)

222812_s_at

-2.7

RHOF

ras homolog gene family, member F (in filopodia)

202278_s_at
225772_s_at

-2.7
-2.7

SPTLC1
C12orf62

serine palmitoyltransferase, long chain base subunit 1
chromosome 12 open reading frame 62

214639_s_at

-2.7

HOXA1

homeobox A1

208467_at

-2.6

KLF12

Kruppel-like factor 12

214773_x_at

-2.6

TIPRL

TIP41, TOR signaling pathway regulator-like (S. cerevisiae)

222508_s_at

-2.6

ARGLU1

arginine and glutamate rich 1

224443_at
218357_s_at

-2.6
-2.6

C1orf97
TIMM8B

chromosome 1 open reading frame 97
translocase of inner mitochondrial membrane 8 homolog B (yeast)

225065_x_at

-2.6

NCRNA00188

non-protein coding RNA 188

205013_s_at

-2.6

ADORA2A

adenosine A2a receptor

1554193_s_at

-2.5

MANEA

mannosidase, endo-alpha

209364_at

-2.5

BAD

BCL2-associated agonist of cell death

215346_at
233124_s_at

-2.5
-2.4

CD40
ECHDC1

CD40 molecule, TNF receptor superfamily member 5
enoyl Coenzyme A hydratase domain containing 1

235244_at
200002_at
1559747_at
226090_x_at
208490_x_at
200834_s_at
204350_s_at
208447_s_at
205967_at
217691_x_at
239114_at
206562_s_at
221563_at
210733_at
225309_at
222837_s_at
217714_x_at
208092_s_at
209204_at
1554780_a_at
243492_at
209743_s_at
200025_s_at
217960_s_at
203034_s_at
203025_at
200099_s_at
205145_s_at
200012_x_at
223682_s_at
229751_s_at
200095_x_at
220669_at
200026_at
200032_s_at
233746_x_at
200674_s_at
213941_x_at
1554342_s_at
222600_s_at
204097_s_at
204833_at
227086_at
202905_x_at
233819_s_at
208695_s_at
211074_at
223584_s_at
217981_s_at
210048_at
201049_s_at

-2.4
-2.4
-2.4
-2.4
-2.3
-2.3
-2.3
-2.3
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.1
-2.1
-2.1
-2.1
-2.1
-2.1
-2.1
-2.1
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-1.9
-1.9
-1.9
-1.9
-1.8
-1.8
-1.8
-1.8
-1.8
-1.8
-1.8
-1.8
-1.8
-1.8

CCDC58
RPL35
SPG11
RABL3
HIST1H2BF
RPS21
MED7
PRPS1
HIST1H4C
SLC16A3
SERGEF
CSNK1A1
DUSP10
TRAM1
PHF5A
NARG1
STMN1
FAM49A
LMO4
PHTF2
THEM4
ITCH
RPL27
TOMM22
RPL27A
ARD1A
RPS3A
MYL5
RPL21
EIF1AD
PUS7L
RPS10
OTUD4
RPL34
RPL9
C15orf63
RPL32
RPS7
HELQ
UBA6
RBMX2
ATG12
C22orf39
NBN
RNF160
RPL39
FOLR1
KBTBD2
FXC1
NAPG
RPS18

coiled-coil domain containing 58
ribosomal protein L35
spastic paraplegia 11 (autosomal recessive)
RAB, member of RAS oncogene family-like 3
histone cluster 1, H2bf
ribosomal protein S21
mediator complex subunit 7
phosphoribosyl pyrophosphate synthetase 1
histone cluster 1, H4c
solute carrier family 16, member 3 (monocarboxylic acid transporter 4)
secretion regulating guanine nucleotide exchange factor
casein kinase 1, alpha 1
dual specificity phosphatase 10
translocation associated membrane protein 1
PHD finger protein 5A
NMDA receptor regulated 1
stathmin 1
family with sequence similarity 49, member A
LIM domain only 4
putative homeodomain transcription factor 2
thioesterase superfamily member 4
itchy E3 ubiquitin protein ligase homolog (mouse)
ribosomal protein L27
translocase of outer mitochondrial membrane 22 homolog (yeast)
ribosomal protein L27a
ARD1 homolog A, N-acetyltransferase (S. cerevisiae)
ribosomal protein S3A
myosin, light chain 5, regulatory
ribosomal protein L21
eukaryotic translation initiation factor 1A domain containing
pseudouridylate synthase 7 homolog (S. cerevisiae)-like
ribosomal protein S10
OTU domain containing 4
ribosomal protein L34
ribosomal protein L9
chromosome 15 open reading frame 63
ribosomal protein L32
ribosomal protein S7
helicase, POLQ-like
ubiquitin-like modifier activating enzyme 6
RNA binding motif protein, X-linked 2
ATG12 autophagy related 12 homolog (S. cerevisiae)
chromosome 22 open reading frame 39
nibrin
ring finger protein 160
ribosomal protein L39
folate receptor 1 (adult)
kelch repeat and BTB (POZ) domain containing 2
fracture callus 1 homolog (rat)
N-ethylmaleimide-sensitive factor attachment protein, gamma
ribosomal protein S18

219484_at
216954_x_at
213875_x_at
203677_s_at
225106_s_at
203610_s_at
226351_at
226727_at
211537_x_at
225172_at
241727_x_at
204906_at
215790_at
65718_at
227204_at
47069_at
1552770_s_at
238593_at
219596_at
232102_at
216912_at
235616_at
235635_at
205019_s_at
244655_at
201906_s_at
1556062_at
201596_x_at
205606_at
239153_at
223672_at
236094_at
224310_s_at
229084_at
207995_s_at
1553808_a_at

-1.8
-1.8
-1.7
-1.7
-1.7
-1.7
-1.6
-1.6
-1.5
1.5
1.6
1.8
1.8
1.9
1.9
2.0
2.1
2.2
2.2
2.3
2.4
2.5
2.6
2.6
2.7
2.8
2.8
2.9
2.9
2.9
3.0
3.0
3.1
3.2
3.5
4.8

HCFC2
ATP5O
C6orf62
TARBP2
OGFOD1
TRIM38
NSUN4
CISD3
MAP3K7
CRAMP1L
DHFRL1
RPS6KA2
AJAP1
GPR124
PARD6G
PRR5
ZNF563
C11orf80
THAP10
METTL6
ARHGEF4
TSHZ2
ARHGAP5
VIPR1
LOC100132798
CTDSPL
RPP30
KRT18
LRP6
HOTAIR
SGIP1
TCF7L2
BCL11B
CNTN4
CLEC4M
NKX2-3

host cell factor C2
ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit
chromosome 6 open reading frame 62
TAR (HIV-1) RNA binding protein 2
2-oxoglutarate and iron-dependent oxygenase domain containing 1
tripartite motif-containing 38
NOL1/NOP2/Sun domain family, member 4
CDGSH iron sulfur domain 3
mitogen-activated protein kinase kinase kinase 7
Crm, cramped-like (Drosophila)
dihydrofolate reductase-like 1
ribosomal protein S6 kinase, 90kDa, polypeptide 2
adherens junctions associated protein 1
G protein-coupled receptor 124
par-6 partitioning defective 6 homolog gamma (C. elegans)
proline rich 5 (renal)
zinc finger protein 563
chromosome 11 open reading frame 80
THAP domain containing 10
methyltransferase like 6
Rho guanine nucleotide exchange factor (GEF) 4
teashirt zinc finger homeobox 2
Rho GTPase activating protein 5
vasoactive intestinal peptide receptor 1
similar to hCG1774772
CTD(carboxy-terminal domain,RNA pol II,polypeptide A) small phosphatase-like
ribonuclease P/MRP 30kDa subunit
keratin 18
low density lipoprotein receptor-related protein 6
hox transcript antisense RNA (non-protein coding)
SH3-domain GRB2-like (endophilin) interacting protein 1
transcription factor 7-like 2 (T-cell specific, HMG-box)
B-cell CLL/lymphoma 11B (zinc finger protein)
contactin 4
C-type lectin domain family 4, member M
NK2 transcription factor related, locus 3 (Drosophila)

Supplemental Table S2. Differentially Expressed Genes between Pediatric (n = 45) and Adult (n = 17) mBL

Probe set
212589_at
1553499_s_at
205081_at
219667_s_at
209131_s_at
206632_s_at
203771_s_at
221142_s_at
203642_s_at
223136_at
219696_at
225735_at
221997_s_at
215011_at
209826_at
214600_at
232821_at
205432_at
230424_at
237905_at
227512_at
229792_at
219491_at
221558_s_at
1566737_at
1564254_at
1556425_a_at
239317_at
1553443_at
206752_s_at
1556609_at
239188_at
230708_at
213283_s_at
239980_at
233100_at
1555353_at
237891_at
1553602_at
233742_at
234221_at
242957_at
206404_at
207199_at
1562484_at
1559688_at

Fold-Change
Ped:Adult
-4.6
-4.5
-3.7
-3.6
-3.6
-3.4
-3.3
-3.0
-2.9
-2.6
-2.3
2.0
2.0
2.1
2.2
2.2
2.2
2.4
2.4
2.4
2.5
2.6
2.6
2.6
2.6
2.6
2.6
2.7
2.7
2.7
2.7
2.7
2.7
2.7
2.8
2.8
2.8
2.8
2.8
2.9
2.9
2.9
3.0
3.2
3.2
3.2

Gene symbol
RRAS2
SERPINA9
(GCET1)
CRIP1
BANK1
SNAP23
APOBEC3B
BLVRA
PECR
COBLL1
AIG1
DENND1B
ANKRD50
MRPL52
SNHG3
PPT2
TEAD1
GTSF1L
OVGP1
C5orf13
KRT25
MEX3A
KLHL17
LRFN4
LEF1
hCG_2036596
KY
LOC284219
CEACAM21
C8orf54
DFFB
LOC401098
PPP2R3C
PRICKLE1
SALL2
C22orf28
EEPD1
LRP1
MDM2
MUCL1
C16orf68
BCAS1
VWCE
FGF9
TERT
FLJ35848
LOC400581

Description
related RAS viral (r-ras) oncogene homolog 2
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9
cysteine-rich protein 1 (intestinal)
B-cell scaffold protein with ankyrin repeats 1
synaptosomal-associated protein, 23kDa
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B
biliverdin reductase A
peroxisomal trans-2-enoyl-CoA reductase
COBL-like 1
androgen-induced 1
DENN/MADD domain containing 1B
ankyrin repeat domain 50
mitochondrial ribosomal protein L52
small nucleolar RNA host gene 3 (non-protein coding)
palmitoyl-protein thioesterase 2
TEA domain family member 1 (SV40 transcriptional enhancer factor)
gametocyte specific factor 1-like
oviductal glycoprotein 1, 120kDa
chromosome 5 open reading frame 13
keratin 25
mex-3 homolog A (C. elegans)
kelch-like 17 (Drosophila)
leucine rich repeat and fibronectin type III domain containing 4
lymphoid enhancer-binding factor 1
hCG2036596
kyphoscoliosis peptidase
hypothetical protein LOC284219
carcinoembryonic antigen-related cell adhesion molecule 21
chromosome 8 open reading frame 54
DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase)
hypothetical LOC401098
protein phosphatase 2 (formerly 2A), regulatory subunit B'', gamma
prickle homolog 1 (Drosophila)
sal-like 2 (Drosophila)
chromosome 22 open reading frame 28
endonuclease/exonuclease/phosphatase family domain containing 1
low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)
Mdm2 p53 binding protein homolog (mouse)
mucin-like 1
chromosome 16 open reading frame 68
breast carcinoma amplified sequence 1
von Willebrand factor C and EGF domains
fibroblast growth factor 9 (glia-activating factor)
telomerase reverse transcriptase
hypothetical protein FLJ35848
GRB2-related adaptor protein-like

240088_at
226610_at
1553185_at
214265_at
209493_at
210063_at
231743_at
217520_x_at
224918_x_at
227377_at
207961_x_at
214131_at
212504_at
213920_at
237461_at
218824_at
204914_s_at

3.2
3.5
3.5
3.5
3.7
3.7
3.7
4.0
4.2
4.4
4.4
4.6
5.3
5.6
7.7
8.3
30.3

PDE5A
CENPV
RASEF
ITGA8
PDZD2
SARDH
WNT3
LOC731884
MGST1
IGF2BP1
MYH11
CYorf15B
DIP2C
CUX2
NLRP7
PNMAL1
SOX11

phosphodiesterase 5A, cGMP-specific
centromere protein V
RAS and EF-hand domain containing
integrin, alpha 8
PDZ domain containing 2
sarcosine dehydrogenase
wingless-type MMTV integration site family, member 3
similar to programmed cell death 6 interacting protein
microsomal glutathione S-transferase 1
insulin-like growth factor 2 mRNA binding protein 1
myosin, heavy chain 11, smooth muscle
chromosome Y open reading frame 15B
DIP2 disco-interacting protein 2 homolog C (Drosophila)
cut-like homeobox 2
NLR family, pyrin domain containing 7
PNMA-like 1
SRY (sex determining region Y)-box 11

Supplemental Table S3. Differentially expressed miRNA between molecularly classified BL (n=31) and DLBCL (n=58) determined
by SAM analysis (FDR = 0.1)

miRNA ID
miR-296-3p
miR-339-5p
miR-128
miR-296-5p
miR-597
miR-130b
miR-92a
miR-18a
miR-18b
miR-19a
miR-20b
miR-17
miR-106a
miR-19b
miR-20a
miR-125b
miR-99a
miR-100
miR-199a-3p
miR-455-5p
miR-29c
miR-29a
miR-29b
miR-23a
miR-22
miR-34a
miR-21
miR-340
miR-150
miR-342-5p
miR-222
miR-146a
miR-155
miR-135b
miR-708

Fold change
BL:DLBCL
5.0
2.9
2.4
2.8
2.2
2.3
2.6
3.7
3.7
3.6
3.8
3.6
3.4
2.9
3.3
-2.1
-1.9
-2.0
-2.1
-2.5
-2.1
-2.0
-2.6
-3.0
-2.5
-2.2
-2.7
-2.0
-2.8
-7.0
-3.0
-2.7
-7.5
-3.9
-2.4

Parametric
p-value
1.5E-04
1.4E-05
2.1E-05
6.1E-06
1.0E-07
5.7E-06
3.1E-05
1.0E-07
1.0E-07
1.0E-07
1.0E-07
1.0E-07
1.0E-07
1.0E-07
2.0E-07
2.1E-04
5.8E-03
3.8E-03
6.8E-06
8.5E-06
1.7E-04
3.9E-04
5.7E-05
1.2E-06
4.1E-06
1.4E-04
4.0E-06
4.4E-04
1.6E-03
2.0E-06
4.3E-05
9.5E-05
1.0E-07
3.0E-04
1.4E-04

Supplemental Table S4. Complete

list of minimal common regions (MCR) of gain (n=16) and loss (n=18) observed in two or more pediatric mDLBCL

specimens
(A) Gains
Cytoband

Start (bp)

End (bp)
147978058

#
cases
5

#
genes
36

1q21.1

143711033

2p15

MCR Genes*

63326947

63429296

3

1

ACP6, ANKRD34, ANKRD35,BCL9, CD160, CHD1L, FAM108A3, FMO5, GJA5, GJA8,
GPR89A, GPR89B, GPR89C, HFE2,ITGA10, LIX1L, LOC728912, NBPF10, NBPF11,
NBPF14, NBPF15, NBPF16 NOTCH2NL,NUDT17,PDE4DIP, PDZK1, PEX11B, PIAS3,
POLR3C, POLR3GL, PPIAL4, PRKAB2, RBM8A, SEC22B, TXNIP, ZNF364
LOC51057

2p11.2
3q21.3

86874328
130316240

87344242
130470589

5
3

5
4

CD8B,RGPD1,RGPD2,PLGLB1,PLGLB2
RAB43,COPG,ISY1,CNBP

3q27.3
5p15.33
5q35.3
11q13.1

188988884
771021
177317148
66089648

189230771
874726
177444039
66917537

3
3
3
9

0
1
3
23

12q13.11
12q15
12q21.32
12q24.33
16q22.1
17q21.33
19q13.2
20q13.33

46451025
68166895
85646042
131822017
66955933
45184550
45922835
61628090

46652716
68283401
85784777
132287718
67070888
45299835
45961895
61776652

5
5
3
3
3
6
4
5

4
2
1
9
1
3
3
7

ZDHHC11
PROP1, LOC653316,LOC653314
ADRBK1,ANKRD13D ,C11orf80,CCDC87,CCS,CLCF1,CTSF, FBXL11,KIAA1394,
LRFN4, PC,POLD4,PPP1CA,RAD9A,RBM14, RBM4, RBM4B, RCE1, RHOD, SPTBN2,
SSH3, SYT12, TBC1D10C
FLJ20489,HDAC7A,VDR,TMEM106C
FRS2,CCT2
MGAT4C
CHFR, GOLGA3, KIAA0692, ZNF10, ZNF140, ZNF26, ZNF268, ZNF605,ZNF84
SMPD3
FAM117A, MYST2,TAC4
ITPKC,C19orf54,SNRPA
PTK6, SRMS, C20orf195, PRIC285, GMEB2, STMN3, RTEL1

(B) Losses

233535919
109814503
197965421
40308822
111833304

#
cases
3
4
6
2
3

#
genes
3
2
6
2
35

137402985
4783100
100419510
81579330
145327191

138565621
4941029
100586851
81665747
145654320

4
2
3
6
3

7
4
4
2
14

11p15.5
12q24.31
16p11.2

878150
122148808
29580704

1053247
122217919
29926001

4
3
4

3
2
16

19p13.3

5605449

5951313

5

17

19p13.2

12502060

13115875

6

31

19q13.12
19q13.2
19q13.32

42133205
46997883
51790267

42312088
47120607
52210724

8
8
4

2
6
10

Cytoband

Start (bp)

End (bp)

2q37.1
2q13
3q29
4p14
6q21

233408623
109614467
197759362
40025322
107466427

6q23.3
7p22.1
7q22.1
8q21.13
8q24.3

MCR Genes*
TNRC15,NGEF,UNQ830
SH3MD4,SEPT10
WDR53,FBXO45,LRRC33,C3orf34,PIGX,PAK2
CHRNA9,FLJ20273
AMD1, ARMC2, BXDC1, C6orf182, C6orf199, C6orf203, CD164,CDC2L6, CDC40, DDO,
FIG4, FLJ25791, FLJ42177,FOXO3, GPR6, GTF3C6,KIAA1553, KIAA1919, LACE1,
MICAL1, NR2E1, OSTM1, PDSS2,PPIL6,REV3L,SCML4, SEC63,SESN1, SLC16A10,
SLC22A16, SMPD2, SNX3, SOBP, WASF1, ZBTB24
IL20RA, IL22RA2,IFNGR1, OLIG3, TNFAIP3, PERP, KIAA1244
KIAA0415, RADIL, PAPOLB, MMD2
MUC17, TRIM56, SERPINE1, AP1S1
ZBTB10, LOC389672
ADCK5, BOP1, C8orf30A, CPSF1, DGAT1, FBXL6, GPR172A, HSF1, KIAA1833, NFKBIL2,
SCRT1, SCXB, SLC39A4, VPS28,
CHID1,AP2A2,MUC6
PITPNM2,MPHOSPH9, RHOF
ASPHD1, C16orf53,C16orf54,CCDC95, CDIPT, DOC2A,HIRIP3,KCTD13,LOC124446,MAZ,
MVP, PRRT2, QPRT, SEZ6L2, SPN, TAOK2
CAPS,DUS3L, FUT3, FUT5, FUT6, HSD11B1L, LONP1, MGC24975, NDUFA11, NRTN,
P117, RANBP3, RFX2, RPL36, SAFB, TMEM146, VMAC
ASNA1, BEST2, BTBD14B, C19orf43, C19orf56, CALR, ,DAND5, DHPS, DNASE2, FARSA,
FBXW9,GADD45GIP1,GCDH, HOOK2,JUNB,KLF1,LYL1,MAN2B1,MAST1,MORG1,NFIX,
PRDX2,RAD23A, RNASEH2A,RTBDN,SYCE2,TNPO2,TRMT1,ZNF490,ZNF564,ZNF791,
ZNF568,ZNF420
CEACAM3, LYPD4,DMRTC2,RPS19,CD79A, ARHGEF1
CALM3, PTGIR, GNG8,DACT3,PRKD2,STRN4, FKRP,SLC1A5,AP2S1,GRLF1

* MCR genes lists all genes residing in an MCR by RefSeq Gene Symbol. Genes listed in bold demonstrated a significant correlation between gene
expression and DNA copy number as determined by one-sided t-test (p < 0.05).

Supplemental Figure Legends
Figure S1. Overall survival of pediatric and adult patients according to treatment and molecular
diagnosis. Pediatric patients are defined as ≤ 20 years of age. Pediatric DLBCL (black) and Pediatric
BL (blue) include all pediatric cases with available clinical data. Adult DLBCL are stratified according
to CHOP (yellow) or R-CHOP (aqua) treatment. Pediatric DLBCL CHOP (pink) includes 6 pediatric
cases younger than 20 years who were treated similar to adult DLBCL with a CHOP-like regimen.
Figure S2. Differential gene expression between adult (n = 51) and pediatric (n = 13) molecularlydefined GCB DLBCL, as determined by SAM analysis (FDR = 0.1).
Figure S3. Differential gene expression between adult (n = 17) and pediatric (n = 45) mBL, as
determined by SAM analysis (FDR = 0.1).
Figure S4. Chromosomal imbalances in pediatric mDLBCL according to molecular subtype.
Genomewide copy number alterations (CNA) are shown as gains to the right and losses to the left of
each chromosome. CNA are color-coded according to the molecular classification of DLBCL subtype.
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Figure S2. Differential gene expression between adult and pediatric mGCB by SAM analysis
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Figure S3. Differential gene expression between adult and pediatric mBL by SAM analysis
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Figure S4. Chromosomal imbalances in pediatric mDLBCL
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